Clearmind Medicine Inc. 已签署一项协议，旨在评估其药物Meai与替尔泊肽（Tirzepatide）联合使用及序贯治疗的潜力，以挑战当前市场上火爆的GLP-1类药物。
该研究将深入探索Meai与替尔泊肽的协同效应，以及不同用药顺序可能带来的疗效差异。此举标志着Clearmind Medicine正积极切入巨大的代谢疾病治疗市场，直接对标已成“爆款”的GLP-1受体激动剂。
通过这项协议，Clearmind Medicine希望为肥胖症、糖尿病等疾病的治疗提供新的、可能更具优势的联合方案。市场将密切关注其后续研究进展，看其能否在竞争激烈的GLP-1领域开辟出新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.